Securities code: China Meheco Group Co.Ltd(600056) securities abbreviation: China Meheco Group Co.Ltd(600056) Announcement No.: Lin 2022012 China Meheco Group Co.Ltd(600056)
Risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important:
China Meheco Group Co.Ltd(600056) (hereinafter referred to as “the company” or “the company”) had eight price limits in the 11 trading days from March 2, 2022 to March 16, 2022, with a cumulative increase of 147.66%, and had touched the abnormal fluctuation of stock trading four times. As of the closing date of March 16, 2022, upon inquiry of wind information, the median price earnings ratio (TTM) of the pharmaceutical circulation industry is 15.35, and the company’s price earnings ratio (TTM) is 32.34, which is significantly higher than the price earnings ratio of the same industry. Please pay attention to the transaction risk of the secondary market.
In the evening of March 15th, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), Pfizer Inc COVID-19 virus treatment drug PAXLOVID ™ (hereinafter referred to as the “product”) has been included in the ninth edition of the diagnosis and treatment plan, but has not entered the national medical insurance for the time being. If it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are affected by factors such as epidemic prevention and control, and there is great uncertainty. It is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
The recent rise of the company’s share price may have exceeded the impact of relevant matters on the company’s performance, and there may be irrational investment. The company once again reminds investors to pay attention to investment risks, make rational decisions and invest prudently.
According to the relevant provisions of the trading rules of Shanghai Stock Exchange, the company has issued the announcement of abnormal fluctuations in stock trading four times on March 4, March 8, March 12 and March 16, 2022, and the announcement of risk warning twice on March 5 and March 15, 2022. On March 16, 2022, the company’s shares rose again. In view of the large fluctuation of the company’s share price recently, the relevant risks are as follows:
1、 There is no significant change in the company’s main business
The company’s main business segments include pharmaceutical industry, pharmaceutical commerce and international trade. At present, the production and operation activities are normal without significant changes.
2、 Transaction risk prompt of secondary market
From March 2, 2022 to March 16, 2022, the company’s shares rose by the limit eight times in 11 trading days, with the cumulative increase of 147.66%, and has touched the abnormal fluctuation of stock trading four times. As of the closing date of March 16, 2022, upon inquiry of wind information, the median price earnings ratio (TTM) of the pharmaceutical circulation industry is 15.35, and the company’s price earnings ratio (TTM) is 32.34, which is significantly higher than the price earnings ratio of the same industry. In view of the large fluctuation range of the company’s share price, please pay attention to the transaction risk of the secondary market, make rational decisions and invest prudently.
3、 Risk tips on cooperation with Pfizer
The company signed an agreement with Pfizer on March 9, 2022. The company will be responsible for Pfizer covid-19 virus treatment drug paxlovid during the agreement period (2022) ™ Business operation in the Chinese mainland market. On February 11, 2022, the State Drug Administration approved the import registration of the product with conditions. The product was a prescription drug. In the evening of March 15th, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), which was included in the ninth edition of the diagnosis and treatment plan, but it has not yet entered the national health insurance. If it is included in the national medical insurance, it may have an impact on the sales price. The final use and sales of the product are affected by factors such as epidemic prevention and control, and there is great uncertainty. It is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
The media of the information disclosure website designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN.) Please refer to the notice of securities investment times and the notice of securities investors on the websites of the securities investment times and the securities company.
It is hereby announced.
China Meheco Group Co.Ltd(600056) board of directors March 17, 2022
